Perforator-sparing basilar artery reconstruction normalizes pathological hemodynamics in vertebrobasilar dolichoectasia: a CFD study

保留穿支血管的基底动脉重建术可使椎基底动脉扩张症的病理性血流动力学恢复正常:一项计算流体动力学研究

阅读:1

Abstract

BACKGROUND: Vertebrobasilar dolichoectasia (VBD) carries high risks of stroke and hemorrhage, yet current treatments remain suboptimal and often compromise critical pontine perforators (PPs). We used computational fluid dynamics (CFD) to evaluate a novel hemodynamically-guided, perforator-sparing reconstruction strategy. METHODS: Patient-specific CFD models from 24 VBD patients were compared with 24 age-sex-matched controls and virtual post-intervention models simulating idealized partial anterior basilar artery (BA) lumen reduction to establish hemodynamic optimization targets while preserving posterior wall PPs. Transient simulations quantified pressure, velocity, time-averaged wall shear stress (TAWSS), oscillatory shear index (OSI), and relative residence time (RRT) within the BA and nine modeled PPs per case. RESULTS: Untreated VBD exhibited pathological hemodynamics: elevated aneurysmal pressure (101.73 ± 0.28 vs. 100.59 ± 0.87 mmHg, p < 0.001), flow stasis (velocity: 5.53 ± 3.52 vs. 12.41 ± 3.44 cm/s, p < 0.001), reduced TAWSS (0.007 ± 0.004 vs. 0.03 ± 0.01 Pa, p < 0.001), and increased OSI (0.07 ± 0.04 vs. 0.01 ± 0.00) and RRT (12.73 ± 13.81 vs. 0.33 ± 0.11 /Pa, all p < 0.001). Perforator hemodynamics remained comparable to controls. Virtual reconstruction of BA normalized all aneurysmal parameters toward physiological levels (Post vs. Pre: all p < 0.001) without adversely affecting hemodynamics in the modeled PPs under the assumptions of the CFD framework. Strong correlations existed between BA volume and adverse hemodynamics, with therapeutic benefits approaching saturation at about 250 mm(3). CONCLUSION: This in silico study demonstrates that perforator-sparing partial reconstruction can normalize VBD's pathological hemodynamics without adversely affecting hemodynamics in the modeled PPs, and establishes a quantitative framework for future endovascular device development, though clinical translation requires validation through experimental models and prospective trials.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。